KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Biolife Solutions (BLFS) over the last 16 years, with Q3 2025 value amounting to $782000.0.

  • Biolife Solutions' Change in Receivables rose 47596.15% to $782000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 16843.22%. This contributed to the annual value of $2.9 million for FY2024, which is 11888.48% up from last year.
  • Biolife Solutions' Change in Receivables amounted to $782000.0 in Q3 2025, which was up 47596.15% from $893000.0 recorded in Q2 2025.
  • Biolife Solutions' Change in Receivables' 5-year high stood at $7.0 million during Q2 2022, with a 5-year trough of -$5.9 million in Q4 2023.
  • In the last 5 years, Biolife Solutions' Change in Receivables had a median value of $893000.0 in 2025 and averaged $531947.4.
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 54973.38% in 2023, then surged by 47596.15% in 2025.
  • Quarter analysis of 5 years shows Biolife Solutions' Change in Receivables stood at $3.0 million in 2021, then tumbled by 56.05% to $1.3 million in 2022, then tumbled by 549.73% to -$5.9 million in 2023, then soared by 120.85% to $1.2 million in 2024, then tumbled by 36.58% to $782000.0 in 2025.
  • Its Change in Receivables was $782000.0 in Q3 2025, compared to $893000.0 in Q2 2025 and -$1000.0 in Q1 2025.